IPO round-up: Lumenis falls short with $75m; Microlin aims for $25m
This article was originally published in Clinica
Israeli laser specialist Lumenis has priced its initial public offering, but the $75m total is well below the $100m it had been looking for. The Yokneam-based company sold 6.3 million shares at $12 each, short of its $15-17 target. However, the underwriters also have a 30-day option to buy another 937,500 shares, which could top up the total raised.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.